- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | 24,54 € / 25,28 € |
| Spread | +3,02% |
| Schluss Vortag | 25,89 € |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief 24,56 € Tageshoch 24,56 € | |
| 52W-Tief 9,604 € 52W-Hoch 28,58 € | |
| Jahrestief 22,71 € Jahreshoch 28,58 € | |
| Umsatz in Mio. | 0,30 $ |
| Operatives Ergebnis (EBIT) in Mio. | -299,04 $ |
| Jahresüberschuss in Mio. | -269,95 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -3,37 $ |
| Gewinnrendite | -40,19% |
| Umsatzrendite | - |
| Return on Investment | -36,36% |
| Marktkapitalisierung in Mio. | 1.535 $ |
| KGV (Kurs/Gewinn) | -5,69 |
| KBV (Kurs/Buchwert) | 2,28 |
| KUV (Kurs/Umsatz) | 4.793 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +90,47% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 24,47 € | -2,55% | 25,11 € | 09:30 | |
| Frankfurt | 24,56 € | -5,14% | 25,89 € | 08:01 | |
| Stuttgart | 24,55 € | -1,05% | 24,81 € | 10:03 | |
| L&S RT | 24,885 € | 0 % | 24,885 € | 10:18 | |
| NYSE | 28,85 $ | -0,16% | 28,895 $ | 05.03.26 | |
| Nasdaq | 28,865 $ | -5,02% | 30,39 $ | 05.03.26 | |
| AMEX | 28,89 $ | -4,61% | 30,285 $ | 05.03.26 | |
| Tradegate | 25,27 € | +1,53% | 24,89 € | 03.03.26 | |
| Quotrix | 24,93 € | -2,92% | 25,68 € | 07:27 | |
| Gettex | 24,56 € | -1,37% | 24,90 € | 10:13 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 05.03.26 | 25,89 | 0 |
| 04.03.26 | 24,77 | 0 |
| 03.03.26 | 25,32 | 0 |
| 02.03.26 | 23,47 | 94 T |
| 27.02.26 | 24,48 | 0 |
| 26.02.26 | 24,36 | 2.436 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 24,36 € | +6,28% |
| 1 Monat | 25,07 € | +3,27% |
| 6 Monate | 15,735 € | +64,54% |
| 1 Jahr | 14,10 € | +83,62% |
| 5 Jahre | 12,68 € | +104,18% |
| Marktkapitalisierung | 1,42 Mrd. € |
| Aktienanzahl | 52,59 Mio. |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +14,99% | FMR Inc |
| +6,76% | BlackRock Inc |
| +6,59% | Deep Track Capital, LP |
| +5,97% | COMMODORE CAPITAL LP |
| +5,52% | Vanguard Group Inc |
| +5,42% | Kynam Capital Management, LP |
| +4,75% | VR Adviser, LLC |
| +4,24% | Fairmount Funds Management LLC |
| +3,55% | T. Rowe Price Associates, Inc. |
| +3,48% | TANG CAPITAL MANAGEMENT LLC |
| +3,36% | Paradigm Biocapital Advisors LP |
| +3,13% | State Street Corp |
| +2,91% | Novo A/S |
| +2,76% | Maverick Capital Ltd |
| +2,38% | AllianceBernstein L.P. |
| +2,33% | Eversept Partners, LLC |
| +2,14% | Baker Bros Advisors LP |
| +2,13% | Geode Capital Management, LLC |
| +1,64% | Loomis, Sayles & Company LP |
| +1,59% | Parkman Healthcare Partners LLC |
| +14,36% | Weitere |
| 0,00% | Streubesitz |
Zahlen für Q1/21
Company believes that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2024
VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing; on track for IND filings in fourth quarter of 2021
http://investors.miragen.com/press-releases/press-release/2021/Viridian-Therapeutics-Reports-First-Quarter-2021-Financial-Results-and-Provides-Corporate-Updates/default.aspx
